ESTRO 2024 - Abstract Book

S2108

Clinical - Sarcoma, skin cancer, melanoma

ESTRO 2024

disease free survival was 31.6 months, atthree years it was 52%. Three-years local control and metastases free survival ware 87% and 78%,respectively.

Conclusion:

These findings suggest that neoadjuvant RT combined with radiative HTholdspromise in the management of STS, although larger studies are warranted to validate these results

Keywords: Hyperthermia

1956

Poster Discussion

NEOADJUVANT CONCURRENT GEMCITABINE AND RADIOTHERAPY FOR SOFT TISSUE SARCOMA

pasquale trecca 1 , carlo greco 1,2 , michele fiore 2,1 , edy ippolito 1,2 , chiara demofonti 1 , salvatore minuti 2 , pierluigi falco 2 , beniamino brunetti 3 , sergio valeri 4 , bruno vincenzi 5,6 , sara ramella 2,1 1 Fondazione Policlinico Universitario Campus Bio-Medico, radiation Oncology, roma, Italy. 2 Università Campus Bio Medico di Roma, radiation Oncology, roma, Italy. 3 Fondazione Policlinico Universitario Campus Bio-Medico, Plastic, Reconstructive and Aesthetic Surgery, roma, Italy. 4 Fondazione Policlinico Universitario Campus Bio-Medico, General Surgery, roma, Italy. 5 Fondazione Policlinico Universitario Campus Bio-Medico, medical Oncology, roma, Italy. 6 Università Campus Bio-Medico di Roma, rMedical Oncology, roma, Italy

Purpose/Objective:

Surgery is the mainstay of treatment for Soft tissue sarcomas (STS) and is the only curative treatment option. The integration of surgery with neoadjuvant radiotherapy (RT) or chemotherapy for resectable tumoris an option that needs multidisciplinary discussion. Gemcitabine is a radiosensitizer with activity in STS. The purpose of this study was to evaluate the efficacy and toxicity of concomitant RT and gemcitabine in the neoadjuvant setting for STS.

Material/Methods:

A retrospective analysis of 19 patients treated with concurrent RT and gem from 2018 to 2022 in a neoadjuvant setting was performed. Radiative hyperthermia treatment was also performed in 9 patients since available in our Center. The RT prescription dose was for all patients 50 Gy in 25 fractions over 5 weeks. Gemcitabine was administered at 300 mg/m2 once weekly for the duration of RT.

Results: